规格: | 98% |
分子量: | N/A |
包装 | 价格(元) |
50mg | 询价 |
100mg | 询价 |
250mg | 询价 |
Background:
Concanamycin A belongs to the concanamycins, a family of macrolide antibiotics isolated from Streptomyces diastatochromogenes that are highly active and selective inhibitors of the vacuolar proton-ATPase (v-[H[+]]ATPase). Among them, concanamycin A is the most selective and potent inhibitor of the V-[H[+]]ATPase.[1]
n vitro study indicated that concanamycin A was active at 5 nM and completely blocked influenza virus infection at 10 nM in MDCK cells. Results showed that concanamycin A blocked viral replication by inhibiting the v-[H[+]]ATPase, thus preventing acidification of endosomes and release of virions into the cytoplasm. An early event in virus infection is the target of concanamytin A. In addition, the inhibition of the v-[H[+]]ATPase by concanamycin A prevents endosomal acidification, inhibiting virus release from endosomes.[1]
参考文献:
[1].Rosario G. et al. Concanamycin A blocks influenza virus entry into cells under acidic conditions. FEBS Letters 1994 June; 349; 327-330.
Protocol:
Cell experiment [1]: | |
Cell lines | CD8+ CTL |
Preparation Method | Cells were cultured in the RPMI 1640 medium supplemented with 10% (v/v) FCS and 5% (v/v) culture supernatant of rat spleen cells. |
Reaction Conditions | Cells were stimulated with 5 μg/ml of concanavalin A for 24 h. |
Applications | Concanavalin A treatment could preferentially decrease the cell viability of CD8+ population prepared from the immunized mice. A certain group(s) of CD8+ population in the immunized mice might be highly susceptible to concanavalin A. The activation through T cell receptors, especially PKC activation, increases the sensitivity of CD8++ CTL to concanavalin A. |
参考文献: [1]. Kenichi T. et al. Concanamycin A, a vacuolar type H+-ATPase inhibitor, induces cell death in activated CD8+ CTL. Cytotechnology 1997 July; 25: 127–135. |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |